Evaxion reports durable three-year responses with EVX-01 in advanced melanoma

Evaxion reported that its EVX-01 Phase 2 trial showed all melanoma patients maintained clinical response with no tumor progression through year three, with 92% still responding at two years and 89% of vaccine neoantigens triggering T-cell responses.

Detected & updated continuously · Source: Nebula